# EARLY ONSET CATARACT IN AN INFANT WITH ACTIVATING **CALCIUM SENSING RECEPTOR (CaSR) MUTATION**



# Priya Ramaswamy<sup>1</sup>, Michael Ryalls<sup>2</sup>, Jeremy Allgrove<sup>1</sup>

1.Barts Health NHS Trust, London, UK

2.Royal Surrey County Hospital, Guildford, UK



# INTRODUCTION

CaSR is a G-protein coupled receptor which senses extracellular levels of calcium ion. Activating CaSR gene variants result in an increased calcium sensitivity in parathyroid and renal cells, which reduces the parathyroid set point and reduces renal calcium re-absorption despite prevailing hypocalcaemia. The clinical presentation varies from mild paraesthesia and muscle cramps to nephrocalcinosis, nephrolithiasis, basal ganglia calcifications and

# **CASE STUDY**

We present a case of a two month old boy with an activating mutation of CaSR who presented with recurrent hypocalcaemic seizures, which settled with parathyroid hormone (PTH) infusion. However, he developed cataract at six weeks of age.

# BACKGROUND

- Male infant, spontaneous vaginal delivery at term
- Second born of healthy non-consanguineous parents \_\_\_\_
- Good condition at birth, Birth Weight 4.19kg \_\_\_\_
- Newborn examination and eye examination normal

# **INVESTIGATIONS**

- **1.5** (2.0–2.7) mmol/l Calcium
- Magnesium 0.6 (0.7 1.0) mmol/l
- Phosphate **3.7**(1.3 2.6) mmol/l \_\_\_\_
- **<0.3** (1.5 7.6) pmol/l PTH

Activating mutation in the CaSR gene confirmed Heterozygous for c.2486A>G, p.(Tyr829Cys)

# **CLINICAL PRESENTATION**

- Admitted at seven days of life with focal seizures \_\_\_\_\_
- Hypocalcaemia with inappropriately low PTH levels
- Treated with intravenous calcium and magnesium \_\_\_\_
- Discharged on oral calcium, magnesium, alfacalcidol \_\_\_\_
- Re-admitted at five weeks; recurrent focal seizures \_\_\_\_\_
- Hypocalcaemia persistent despite treatment
- Stopped fixing and following over the last week
- Nystagmus present and red reflexes absent
- Ophthalmology confirmed dense bilateral cataract \_\_\_\_\_

**Position of Mutations in the CASR** 

A CONSTANT A CONTRACT AND CONTRACT CONTRACT AND C DAEDMAQDØREG#ENYXT#EVSE#RAEDDOD#AAVCX ZDDNAVA SVGSQDA XVA DA PDBE DOODBEEAE ctivating mutations at one site ivating mutations at one site Activating and inactivating mutations at one site Polymorphism Cleavage of the signal sequence

Conserved cysteine

 $\succ$  N-glycosylation

• PKC site

p.Tyr829 is highly conserved across species and lies within the extracellular loop 3 of the CaSR protein, in a region of the protein where a cluster of autosomal dominant hypocalcaemia mutations reside (residues 819—837) (Image obtained from www.casrdb.mcgill.ca)

#### **CLINICAL MANAGEMENT**

- Commenced on subcutaneous PTH infusion
- Weaned off intravenous calcium infusion
- Alfacalcidol stopped and Colecalciferol commenced \_\_\_\_\_
- Seizures settled after resolution of hypocalcaemia
- Thiazides started to reduce renal calcium excretion —
- Urine calcium creatinine ratio was monitored \_\_\_\_\_
- Operated for cataract at nine weeks of life

#### CONCLUSION

(Original figure: L. D'Souza-Li)

- Hypoparathyroidism is known to be associated with cataract formation
- As far as we are aware, this is the first reported case of cataract in infants with activating CaSR mutation, although it has been previously identified in a mouse model
- We therefore suggest that evaluation for cataract is required in this subgroup of patients